Dipartimento di Scienze Farmaceutiche, Università degli Studi di Modena e Reggio Emilia , Via Campi 183, 41125 Modena, Italy.
J Med Chem. 2012 Jan 12;55(1):23-36. doi: 10.1021/jm200421e. Epub 2011 Dec 22.
A series of aralkylphenoxyethylamine and aralkylmethoxyphenylpiperazine compounds was synthesized and their in vitro pharmacological profile at both 5-HT(1A) receptors and α(1)-adrenoceptor subtypes was measured by binding assay and functional studies. The results showed that the replacement of the 1,3-dioxolane ring by a tetrahydrofuran, cyclopentanone, or cyclopentanol moiety leads to an overall reduction of in vitro affinity at the α(1)-adrenoceptor while both potency and efficacy were increased at the 5-HT(1A) receptor. A significant improvement of 5-HT(1A)/α(1) selectivity was observed in some of the cyclopentanol derivatives synthesized (4acis, 4ccis and trans). Compounds 2a and 4ccis emerged as novel and interesting 5-HT(1A) receptor antagonist (pK(i) = 8.70) and a 5-HT(1A) receptor partial agonist (pK(i) = 9.25, pD(2) = 9.03, E(max) = 47%, 5-HT(1A)/α(1a) = 69), respectively. Docking studies were performed at support of the biological data and to elucidate the molecular basis for 5-HT(1A) agonism/antagonism activity.
合成了一系列芳基烷氧基乙胺和芳基烷氧基苯哌嗪化合物,并通过结合测定和功能研究测定了它们在 5-HT(1A)受体和 α(1)-肾上腺素能受体亚型上的体外药理学特性。结果表明,用四氢呋喃、环戊酮或环戊醇取代 1,3-二恶烷环会导致对 α(1)-肾上腺素能受体的体外亲和力整体降低,而对 5-HT(1A)受体的效力和效能都增加。在合成的一些环戊醇衍生物中观察到 5-HT(1A)/α(1)选择性的显著改善(4acis、4ccis 和反式)。化合物 2a 和 4ccis 分别作为新型和有趣的 5-HT(1A)受体拮抗剂(pK(i) = 8.70)和 5-HT(1A)受体部分激动剂(pK(i) = 9.25,pD(2) = 9.03,E(max) = 47%,5-HT(1A)/α(1a)= 69)。进行了对接研究,以支持生物学数据并阐明 5-HT(1A)激动/拮抗活性的分子基础。